Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid

Larralde, Osmany; Petrík, Juraj

doi:10.1007/s00430-017-0507-0

Cited by 11 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phage particles can also be engineered to carry vaccine antigens on their surfaces or they can be used as a vehicle to deliver DNA vaccines (Clark and March 2004). Such structural vaccines can be used to mimic Hepatitis E viral infections (Larralde and Petrik 2017).…”

Section: Indirect Applications Of Bacteriophagementioning

confidence: 99%

Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria

El‐Shibiny

El-Sahhar

2017

Can. J. Microbiol.

View full text Add to dashboard Cite

Since their discovery in 1915, bacteriophages have been used to treat bacterial infections in animals and humans because of their unique ability to infect their specific bacterial hosts without affecting other bacterial populations. The research carried out in this field throughout the 20th century, largely in Georgia, part of USSR and Poland, led to the establishment of phage therapy protocols. However, the discovery of penicillin and sulfonamide antibiotics in the Western World during the 1930s was a setback in the advancement of phage therapy. The misuse of antibiotics has reduced their efficacy in controlling pathogens and has led to an increase in the number of antibiotic-resistant bacteria. As an alternative to antibiotics, bacteriophages have become a topic of interest with the emergence of multidrug-resistant bacteria, which are a threat to public health. Recent studies have indicated that bacteriophages can be used indirectly to detect pathogenic bacteria or directly as biocontrol agents. Moreover, they can be used to develop new molecules for clinical applications, vaccine production, drug design, and in the nanomedicine field via phage display.Key words: bacteriophages, antibiotics, biocontrol, infection, pathogenesis.Résumé : Les bactériophages ont été utilisés pour traiter des infections bactériennes chez l'animal et l'humain depuis leur découverte en 1915, à cause de leur capacité unique d'infecter leurs hôtes bactériens spécifiques, sans affecter les autres populations bactériennes. La recherche réalisée dans ce domaine au cours du vingtième siècle, principalement en Géorgie, dans une partie de l'URSS et en Pologne, a mené à l'établissement de protocoles thérapeutiques à partir de phages. Cependant, la découverte de la pénicilline et des antibiotiques sulfamidés au cours des années 1930 a retardé l'avancement de la thérapie par les phages. Le mauvais usage des antibiotiques depuis leur découverte a résulté en une augmentation du nombre de bactéries résistantes aux antibiotiques et une réduction de leur efficacité à contrôler d'importants pathogènes. Les bactériophages sont devenus un sujet d'intérêt comme alternative aux antibiotiques avec l'émergence de bactéries multirésistantes qui constituent une menace à la santé publique. Des études récentes ont indiqué que les bactériophages peuvent être utilisés indirectement pour détecter les bactéries pathogènes, ou directement, comme agents de contrôle biologique. De plus, ils peuvent être utilisés pour développer de nouvelles molécules à des fins d'applications cliniques, de production de vaccins, dans la conception de médicaments et dans le domaine de la nanomédecine, par l'exposition sur phage. [Traduit par la Rédaction]

show abstract

Section: Indirect Applications Of Bacteriophagementioning

confidence: 99%

Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria

El‐Shibiny

El-Sahhar

2017

Can. J. Microbiol.

View full text Add to dashboard Cite

show abstract

“…And the long peptide epitopes are mostly in the form of spatial conformation. Mimic epitope is a structure in which the sequence is from the discontinuous amino acid of a spatial conformation, and it may have homology to the certain antigens (Larralde and Petrik 2017), or may have no similarity to the antigens at all. Screening of mimic epitopes not only avoids the cumbersome synthesis of long peptides and the purification of recombinant proteins, but also overcomes the low affinity of the long chain amino acids to antibodies due to the helix or folding.…”

Section: Introductionmentioning

confidence: 99%

Serological diagnosis of Mycoplasma pneumoniae infection by using the mimic epitopes

Shi

Zhao

et al. 2018

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Nowadays, there is lack of effective serological detection method for Mycoplasma pneumoniae (M. pneumoniae) infection in clinic. In this study, the mimic epitopes of M. pneumoniae were screened to evaluate the role in the serodiagnosis of M. pneumoniae infection. The M. pneumoniae-positive serum was used as the target for biopanning to phage display random 7-peptide library. The positive phage clones were selected and the DNA were sequenced and analyzed by BLAST. The representative phages were identified using dot immunoblotting and ELISA. The exogenous heptapeptides were synthesized and their reactions with M. pneumonia-positive serum were tested by indirect ELISA. Two heptapeptides, namely heptapeptide 1: TVNFKLY and heptapeptide 2: LPQRLRT, were screened out from the randomly selected 40 phages after the four bio-panning rounds. They had high homologies to some M. pneumoniae antigens. Besides, the representative bacteriophage containing heptapeptide 1 or 2 could react with the M. pneumonia- positive serum. The sensitivities of heptapeptide 1 and heptapeptide 2 for the diagnosis of M. pneumoniae infection were 90.1 and 80.0%, respectively, and the specificities were 94.3 and 97.1%, respectively. Therefore the two heptapeptides were the mimic epitopes of M. pneumoniae and might have potential serological diagnosis value for M. pneumoniae infection.

show abstract

“…93,94 It is crucial to use vaccine to prevent HEV infection, thus knowledge for the structure of the HEV genome and the function of ORFs are essential for vaccine development. [95][96][97][98] Although four genotypes of HEV have been reported globally, they belong to one serotype. The antibodies induced by different genotype HEV can neutralize homologous or heterologous HEV.…”

Section: Discussionmentioning

confidence: 99%

Development of new hepatitis E vaccines

Cao

Bing

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis E virus (HEV) infection is an emerging zoonotic disease posing a severe threat to public health in the world, especially to pregnant women. Currently, no specific treatments are available for HEV infection. Therefore, it is crucial to develop vaccine to prevent this infection. Although several potential candidate vaccines against HEV have been studied for their immunogenicity and efficacy, only Hecolin® which is developed by Xiamen Innovax Biotech Co., Ltd. and approved by China Food and Drug Administration (CFDA) in 2012, is the licensed HEV vaccine in the world so far. Extensive studies on safety, immunogenicity and efficacy in phase III clinical trials have shown that Hecolin® is a promising vaccine for HEV prevention and control. In this article, the advances on HEV vaccine development and research are briefly reviewed.

show abstract

Phage-displayed peptides that mimic epitopes of hepatitis E virus capsid

Cited by 11 publications

References 58 publications

Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria

Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria

Serological diagnosis of Mycoplasma pneumoniae infection by using the mimic epitopes

Development of new hepatitis E vaccines

Contact Info

Product

Resources

About